Aldeyra Therapeutics
ALDX
72 hedge funds and large institutions have $41.4M invested in Aldeyra Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 15 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
6% less funds holding
Funds holding: 77 → 72 (-5)
6.78% less ownership
Funds ownership: 63.33% → 56.55% (-6.8%)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
31% less call options, than puts
Call options by funds: $27K | Put options by funds: $39K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
60% less capital invested
Capital invested by funds: $103M → $41.4M (-$61.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$2.73M |
| 2 |
Renaissance Technologies
New York
|
+$2.33M |
| 3 |
Two Sigma Investments
New York
|
+$353K |
| 4 |
JP Morgan Chase
New York
|
+$252K |
| 5 |
PC
PA Capital
Richmond,
Virginia
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.81M |
| 2 |
6CM
683 Capital Management
New York
|
-$3.61M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$607K |
| 4 |
KC
Kepos Capital
New York
|
-$420K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$352K |
ALDX Hedge Fund Activity: Q1 2020 in Review
72 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2020, worth a combined $41.4M — down 60% from $103M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ALDX and 11 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 22 added.
The largest buyer was Prosight Management, adding an estimated $2.73M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $5.81M sold.
- 72 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2020, down from 77 in Q4 2019.
- Funds reported $41.4M of Aldeyra Therapeutics stock for Q1 2020, down 60% quarter-over-quarter.
- 11 funds opened new Aldeyra Therapeutics positions in Q1 2020 and 15 closed out, a net change of -4 holders.
- The largest Aldeyra Therapeutics buyer in Q1 2020 was Prosight Management, an estimated $2.73M added.
- The largest Aldeyra Therapeutics seller in Q1 2020 was Adage Capital Partners, an estimated $5.81M sold.
Based on aggregated 13F filings for Q1 2020.